Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry

BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment. AIM: The aim of this study was to assess the effectiveness and safety of 24 months of tofa...

Descripción completa

Detalles Bibliográficos
Autores principales: Straatmijer, Tessa, van Schaik, Fiona D. M., Bodelier, Alexander G. L., Visschedijk, Marijn, de Vries, Annemarie C., Ponsioen, Cyriel Y., Pierik, Marieke, van Bodegraven, Ad A., West, Rachel L., de Boer, Nanne K. H., Srivastava, Nidhi, Romkens, Tessa E. H., Hoekstra, Jildou, Oldenburg, Bas, Dijkstra, Gerard, van der Woude, Janneke C., Löwenberg, Mark, Mujagic, Zlatan, Biemans, Vince B. C., van der Meulen‐de Jong, Andrea E., Duijvestein, Marjolijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Tofacitinib in Ulcerative Colitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092078/
https://www.ncbi.nlm.nih.gov/pubmed/36282200
http://dx.doi.org/10.1111/apt.17248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092078/
https://www.ncbi.nlm.nih.gov/pubmed/36282200
http://dx.doi.org/10.1111/apt.17248

Ejemplares similares